Clinical Trial Results:
A Phase 3 Randomized, Double-blind, Parallel-group, Multi-center Study of the Safety
and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill
Medical Subjects During and Following Hospitalization.
ADOPT: Apixaban Dosing to Optimize Protection from Thrombosis
And Pharmacogenetics Blood Sample Amendment 01 - Site Specific (Version 2.0, Date 27-Feb-2007)
Revised Protocol 01 incorporating Amendment 02 and Admin Letter 01 (Version 5.0, date 25-Jan-2008)
Revised protocol 02 incorporating amendment 04 version 7.0 dated 26-Feb-2009
Summary
|
|
EudraCT number |
2006-003674-96 |
Trial protocol |
BE SE NL CZ AT FR DK HU DE IT GB ES |
Global completion date |
18 May 2011
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 Dec 2016
|
First version publication date |
07 Dec 2016
|
Other versions |
|
Summary report(s) |
CV185-036_Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.